Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)
Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that pro...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 19; no. 3; pp. 562 - 568 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Heart Association, Inc
01.03.1999
Hagerstown, MD Lippincott |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. (Arterioscler Thromb Vasc Biol. 1999;19:562-568.) |
---|---|
AbstractList | Abstract
—Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin],
r
=0.38 [
r
=0.34] in normal glucose tolerance;
r
=0.42 [
r
=0.43] in impaired glucose tolerance; and
r
=0.38 [
r
=0.26] in type 2 diabetes; all
P
<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (
r
=0.20 for insulin and proinsulin; each
P
<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. (Arterioscler Thromb Vasc Biol. 1999;19:562-568.) Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic. |
Author | Zaccaro, Daniel J. Haffner, Steven M. Hales, C. Nick Mykkanen, Leena Festa, Andreas Tracy, Russell P. D'Agostino, Ralph |
AuthorAffiliation | Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu |
AuthorAffiliation_xml | – name: Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu |
Author_xml | – sequence: 1 givenname: Andreas surname: Festa fullname: Festa, Andreas organization: Received April 21, 1998; revision accepted August 13, 1998. From the Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio (A.F., L.M., S.M.H.); the Department of Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC (R.D., D.J.Z.); the Department of Pathology, University of Vermont School of Medicine, Burlington (R.P.T.); and the Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK (C.N.H.). Correspondence to Andreas Festa, MD, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7873. E-mail festa@uthscsa.edu – sequence: 2 givenname: Ralph surname: D'Agostino fullname: D'Agostino, Ralph – sequence: 3 givenname: Leena surname: Mykkanen fullname: Mykkanen, Leena – sequence: 4 givenname: Russell P. surname: Tracy fullname: Tracy, Russell P. – sequence: 5 givenname: Daniel J. surname: Zaccaro fullname: Zaccaro, Daniel J. – sequence: 6 givenname: C. Nick surname: Hales fullname: Hales, C. Nick – sequence: 7 givenname: Steven M. surname: Haffner fullname: Haffner, Steven M. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1714088$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10073958$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kkuP0zAUhSM0iHnAmh3yAiFYpGPHjpOwqwozVKpE1SmwtFznempw7WI7jObn8c9waHmIBQs_9Z1zdX18Xpw476AonhI8IYSTS0wm0_XHCekmdFLz6kFxRuqKlYxTfpL3uOnKmrPqtDiP8TPGmFUVflScEowb2tXtWfF9BVYm8w3QzLsUzGZIxjvkNZq7OFjjkHQ9mqeIlgHUEKIPESWPrswmGOdv4QAsp_OSoJFGCxluAS39fhiNs9cnk7bojdEaAriEbpJMEMcK13ZQPgJaewtBOgWv0XoLvwuvIJqYxns0TVsIPio7ziZmj6G_Ry_nq-nNq8fFQy1thCfH9aL4cPV2PXtXLt5fz2fTRalY7rvsK90SaFvG2xa6FkumJe4ZadQGOtbrtiIKq1pDQ_uWMko1h7ppZMVpz6Gq6UXx4uC7D_7rADGJnYkKrJUO_BAF7zhpGeky-OwIDpsd9GIfzE6Ge_Hr0TPw_AjIqKTVY-8m_uEawnA7YpcHTOWmYwD9l5MY0xeYiJy-IJ2gIqefFfU_CmXSzxBSkMb-R8cOujtvE4T4xQ53EMQWpE1bMX4bynFdkq7rMM3HMg_C6A8mUMQ- |
CODEN | ATVBFA |
CitedBy_id | crossref_primary_10_1016_j_medj_2020_06_005 crossref_primary_10_2337_diabetes_53_3_663 crossref_primary_10_1016_j_ecl_2006_06_001 crossref_primary_10_1016_j_ijcard_2005_04_024 crossref_primary_10_1016_j_schres_2007_03_029 crossref_primary_10_1136_bmjopen_2016_013894 crossref_primary_10_1507_endocrj_52_89 crossref_primary_10_3390_nu9040336 crossref_primary_10_2337_db15_1141 crossref_primary_10_1016_j_atherosclerosis_2006_12_018 crossref_primary_10_1016_S0149_2918_01_80140_5 crossref_primary_10_2337_diabetes_53_2_336 crossref_primary_10_2337_diacare_28_10_2472 crossref_primary_10_1016_S0300_8932_01_76390_7 crossref_primary_10_1053_meta_2003_50027 crossref_primary_10_1016_j_carpath_2007_07_007 crossref_primary_10_1016_j_thromres_2006_09_013 crossref_primary_10_1038_sj_ijo_0802192 crossref_primary_10_1210_clinem_dgz171 crossref_primary_10_1371_journal_pone_0067949 crossref_primary_10_4158_EP_13_6_679 crossref_primary_10_1155_2012_635472 crossref_primary_10_1016_j_ejvs_2009_10_014 crossref_primary_10_1016_j_rec_2010_10_011 crossref_primary_10_1016_j_metabol_2006_02_023 crossref_primary_10_1016_j_numecd_2008_07_007 crossref_primary_10_1016_S0002_9149_03_00612_X crossref_primary_10_1007_s00296_008_0781_7 crossref_primary_10_1016_j_arteri_2018_01_002 crossref_primary_10_1177_0003319715602414 crossref_primary_10_1177_153537020122600103 crossref_primary_10_1038_sj_ijo_0801792 crossref_primary_10_18705_1607_419X_2007_13_2_113_118 crossref_primary_10_3748_wjg_v11_i32_5047 crossref_primary_10_1097_01_crd_0000182411_88146_72 crossref_primary_10_1111_j_1600_0404_2008_01080_x crossref_primary_10_1016_S0895_7967_02_70021_5 crossref_primary_10_1517_14728222_2013_764991 crossref_primary_10_2337_diacare_28_9_2289 crossref_primary_10_3390_ijms25052661 crossref_primary_10_2337_diacare_29_03_06_dc05_2023 crossref_primary_10_1046_j_1464_5491_2002_00824_x crossref_primary_10_1079_PHN2003586 crossref_primary_10_1016_S0149_2918_04_90017_3 crossref_primary_10_1016_j_numecd_2007_02_015 crossref_primary_10_1210_jcem_85_7_6677 crossref_primary_10_1016_S0049_3848_01_00293_6 crossref_primary_10_1186_s12902_021_00837_z crossref_primary_10_1016_j_schres_2008_03_004 crossref_primary_10_1177_193229681200600318 crossref_primary_10_1097_SMJ_0b013e3181cf373f crossref_primary_10_1097_00041433_200010000_00010 crossref_primary_10_1177_039463200702000312 crossref_primary_10_2337_diabetes_53_7_1773 crossref_primary_10_1016_S0755_4982_05_84243_5 crossref_primary_10_1016_j_jdiacomp_2006_02_001 crossref_primary_10_1016_j_surg_2010_05_014 crossref_primary_10_1016_j_jacc_2004_11_075 crossref_primary_10_1073_pnas_2121133119 crossref_primary_10_1097_TEN_0b013e3181dfe618 crossref_primary_10_1152_ajpendo_00064_2015 crossref_primary_10_1111_j_1749_6632_2001_tb03936_x crossref_primary_10_1016_j_jacc_2008_10_038 crossref_primary_10_1172_JCI13143 crossref_primary_10_2337_db06_0116 crossref_primary_10_1002_pro_3770 crossref_primary_10_1152_ajpheart_00620_2011 crossref_primary_10_1016_j_schres_2014_08_011 crossref_primary_10_1038_jcbfm_2010_102 crossref_primary_10_1007_s00125_005_1711_9 crossref_primary_10_1590_S1807_59322006000500010 crossref_primary_10_1111_j_1464_5491_2006_01923_x crossref_primary_10_1111_j_1440_1797_2010_01329_x crossref_primary_10_1093_jbcr_irz083 crossref_primary_10_1177_1010539513480233 crossref_primary_10_1055_s_0041_1726613 crossref_primary_10_2337_diacare_24_8_1476 crossref_primary_10_2337_dc07_0637 crossref_primary_10_2337_diacare_25_10_1737 crossref_primary_10_3389_fcvm_2021_769343 crossref_primary_10_1016_j_jdiacomp_2016_06_030 crossref_primary_10_2174_1389201021666201126143217 crossref_primary_10_1134_S2079057015040128 crossref_primary_10_1177_0300060515627561 crossref_primary_10_3132_dvdr_2004_011 crossref_primary_10_1002_dmrr_254 crossref_primary_10_1016_j_eclinm_2020_100548 crossref_primary_10_1016_j_thromres_2010_12_005 crossref_primary_10_1089_154041903321648243 crossref_primary_10_1590_S0004_27302008000300015 crossref_primary_10_1002_ddr_20233 crossref_primary_10_1016_j_jvs_2012_05_078 crossref_primary_10_14341_2072_0351_5995 crossref_primary_10_1016_S0889_8588_02_00086_2 crossref_primary_10_1111_j_1538_7836_2008_03176_x crossref_primary_10_2337_diabetes_51_4_1131 crossref_primary_10_2337_dc07_1540 crossref_primary_10_1016_S0021_9150_01_00574_3 crossref_primary_10_1007_s00125_007_0715_z crossref_primary_10_1053_j_semvascsurg_2016_06_003 crossref_primary_10_1016_S0005_2736_02_00686_7 crossref_primary_10_2337_dc08_1795 crossref_primary_10_1152_ajpregu_00093_2009 crossref_primary_10_1111_j_1365_2796_2004_01371_x crossref_primary_10_2337_diacare_25_3_524 crossref_primary_10_1016_j_annepidem_2017_12_003 crossref_primary_10_1038_nrneurol_2009_231 crossref_primary_10_1016_j_thromres_2009_11_034 crossref_primary_10_1210_jc_2003_030508 crossref_primary_10_18705_1607_419X_2006_12_2_99_116 crossref_primary_10_1016_j_jvs_2010_05_086 crossref_primary_10_1111_j_1365_2265_2007_03113_x crossref_primary_10_1016_j_amjcard_2006_02_022 crossref_primary_10_1111_j_1538_7836_2006_02132_x crossref_primary_10_2337_diabetes_53_6_1549 crossref_primary_10_1080_03008200701331524 crossref_primary_10_1016_S1062_0303_03_00083_9 crossref_primary_10_1046_j_1467_789X_2002_00056_x crossref_primary_10_1080_07853890500401234 crossref_primary_10_1186_1475_2840_13_76 crossref_primary_10_1007_s10900_013_9726_5 crossref_primary_10_1097_YIC_0b013e32801182e6 crossref_primary_10_2337_diabetes_54_5_1566 crossref_primary_10_3389_fcvm_2021_653655 crossref_primary_10_1093_aje_153_3_242 crossref_primary_10_1016_j_amjmed_2003_08_009 crossref_primary_10_1016_j_recesp_2010_10_010 crossref_primary_10_2188_jea_16_64 crossref_primary_10_1038_oby_2002_98 crossref_primary_10_1016_j_numecd_2009_08_006 crossref_primary_10_1016_S0021_9150_01_00575_5 crossref_primary_10_1046_j_1538_7836_2003_00276_x crossref_primary_10_1016_S1134_3230_10_61006_X crossref_primary_10_1007_s10557_008_6101_3 crossref_primary_10_1016_j_ecl_2004_03_008 crossref_primary_10_1016_j_thromres_2014_02_028 crossref_primary_10_1097_MAJ_0b013e3182449ff9 crossref_primary_10_1007_s11892_003_0056_3 crossref_primary_10_1038_srep17714 crossref_primary_10_1046_j_1523_1755_2000_00331_x crossref_primary_10_1016_j_diabres_2005_10_015 crossref_primary_10_1111_j_1365_2796_2007_01824_x crossref_primary_10_2165_00003495_200565010_00003 crossref_primary_10_1016_j_jdiacomp_2006_10_009 crossref_primary_10_1038_s41380_021_01264_1 crossref_primary_10_1079_PNS2005482 crossref_primary_10_1016_j_amjmed_2003_08_014 crossref_primary_10_19163_1994_9480_2017_3_63__16_22 crossref_primary_10_1007_s00125_012_2741_8 crossref_primary_10_1016_j_artere_2018_01_001 crossref_primary_10_1016_j_jstrokecerebrovasdis_2012_12_014 crossref_primary_10_14341_2072_0351_6114 crossref_primary_10_1007_s12975_014_0365_7 crossref_primary_10_1016_j_jacc_2015_06_1328 crossref_primary_10_1016_j_vph_2005_11_009 crossref_primary_10_1186_1476_9255_8_34 crossref_primary_10_1046_j_1365_2265_2003_01714_x crossref_primary_10_1097_00005082_200607000_00012 crossref_primary_10_1089_met_2005_3_147 crossref_primary_10_1586_eem_09_44 crossref_primary_10_1038_s41598_018_30028_1 crossref_primary_10_2165_00129784_200606040_00003 crossref_primary_10_1007_s00125_005_1876_2 |
Cites_doi | 10.1056/NEJM198708063170605 10.1016/1047-2797(95)00062-3 10.2337/diab.44.1.37 10.1093/oxfordjournals.aje.a115134 10.1172/JCI111776 10.1007/BF00404140 10.1016/1047-2797(92)90095-8 10.1161/circ.89.1.8281664 10.2337/diab.41.6.715 10.2337/diab.42.9.1297 10.1016/0049-3848(90)90373-K 10.1016/0026-0495(88)90157-6 10.1055/s-0038-1650395 10.1161/atv91.13.12.8241109 10.1016/0002-8703(90)90026-T 10.1055/s-0038-1653822 10.1016/0895-4356(94)90298-4 10.2337/diab.43.1.104 10.2337/diab.36.8.897 10.2337/diab.42.2.250 10.2337/diab.43.9.1114 10.1161/circ.93.10.1809 10.1016/S0021-9150(96)06070-4 10.1093/oxfordjournals.aje.a113956 10.1007/BF02374497 10.2337/diacare.13.6.631 10.2337/diab.44.4.437 10.1055/s-0038-1646997 10.2337/diacare.19.2.157 10.1093/oxfordjournals.aje.a116768 10.1016/0026-0495(90)90164-8 10.1042/bj2600535 10.1210/edrv-6-1-45 10.3109/07853899608999095 10.1007/BF00402183 10.1055/s-0038-1653762 10.7326/0003-4819-118-12-199306150-00008 10.2337/diacare.15.10.1245 10.1016/S0140-6736(89)91306-8 10.1111/j.0954-6820.1985.tb08888.x 10.1007/BF00403280 10.1056/NEJM198408233110804 10.1161/circ.91.3.764 10.1210/jcem-71-6-1508 10.1093/oxfordjournals.aje.a113639 10.2337/diab.37.12.1595 10.1007/BF00400356 10.1056/NEJM198903163201105 10.1016/0026-0495(93)90005-9 10.1016/0026-0495(86)90209-X 10.1159/000205234 10.2337/diab.41.7.890 10.1016/0169-2607(86)90106-9 10.1161/atvb.18.1.84 10.2337/diacare.14.3.173 10.1210/jcem-25-10-1375 10.1016/0026-0495(88)90133-3 |
ContentType | Journal Article |
Copyright | 1999 American Heart Association, Inc. 1999 INIST-CNRS |
Copyright_xml | – notice: 1999 American Heart Association, Inc. – notice: 1999 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/01.ATV.19.3.562 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 568 |
ExternalDocumentID | 10073958 1714088 10_1161_01_ATV_19_3_562 00043605-199903000-00014 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: HL47889 – fundername: NHLBI NIH HHS grantid: HL47890 – fundername: NHLBI NIH HHS grantid: HL47887 |
GroupedDBID | --- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACGOD ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN AAYXX ADGHP CITATION IQODW ACIJW AWKKM CGR CUY CVF ECM EIF NPM OK1 OLW RHF 7X8 |
ID | FETCH-LOGICAL-c4004-d2f81e884688e980a4fa0d417cbe94df821c0c5fe73d83433f6e577a263d6e253 |
ISSN | 1079-5642 |
IngestDate | Fri Jul 11 12:42:06 EDT 2025 Wed Feb 19 02:34:28 EST 2025 Mon Jul 21 09:12:40 EDT 2025 Tue Jul 01 02:21:41 EDT 2025 Thu Apr 24 23:05:09 EDT 2025 Fri May 16 03:46:45 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Endocrinopathy Vascular disease Human Plasminogen activator inhibitor 1 Target tissue resistance Atherosclerosis Risk factor Fibrinogen Cardiovascular disease Non insulin dependent diabetes Insulin |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4004-d2f81e884688e980a4fa0d417cbe94df821c0c5fe73d83433f6e577a263d6e253 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 10073958 |
PQID | 69618419 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_69618419 pubmed_primary_10073958 pascalfrancis_primary_1714088 crossref_primary_10_1161_01_ATV_19_3_562 crossref_citationtrail_10_1161_01_ATV_19_3_562 wolterskluwer_health_00043605-199903000-00014 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-March |
PublicationDateYYYYMMDD | 1999-03-01 |
PublicationDate_xml | – month: 03 year: 1999 text: 1999-March |
PublicationDecade | 1990 |
PublicationPlace | Philadelphia, PA Hagerstown, MD |
PublicationPlace_xml | – name: Philadelphia, PA – name: Hagerstown, MD – name: United States |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 1999 |
Publisher | American Heart Association, Inc Lippincott |
Publisher_xml | – name: American Heart Association, Inc – name: Lippincott |
References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 (e_1_3_2_53_2) 1995; 73 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_62_2 e_1_3_2_22_2 e_1_3_2_45_2 (e_1_3_2_48_2) 1993; 117 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_60_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_1_2 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_14_2 e_1_3_2_35_2 (e_1_3_2_56_2) 1996; 75 e_1_3_2_50_2 (e_1_3_2_3_2) 1996; 334 (e_1_3_2_46_2) 1994; 118 e_1_3_2_27_2 e_1_3_2_29_2 (e_1_3_2_55_2) 1997; 8 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_63_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_61_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_59_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 |
References_xml | – ident: e_1_3_2_12_2 doi: 10.1056/NEJM198708063170605 – ident: e_1_3_2_34_2 doi: 10.1016/1047-2797(95)00062-3 – ident: e_1_3_2_57_2 doi: 10.2337/diab.44.1.37 – ident: e_1_3_2_36_2 doi: 10.1093/oxfordjournals.aje.a115134 – ident: e_1_3_2_7_2 doi: 10.1172/JCI111776 – ident: e_1_3_2_32_2 doi: 10.1007/BF00404140 – volume: 8 start-page: 1252 year: 1997 ident: e_1_3_2_55_2 publication-title: Diabetes Care – ident: e_1_3_2_62_2 doi: 10.1016/1047-2797(92)90095-8 – ident: e_1_3_2_30_2 doi: 10.1161/circ.89.1.8281664 – ident: e_1_3_2_16_2 doi: 10.2337/diab.41.6.715 – ident: e_1_3_2_33_2 doi: 10.2337/diab.42.9.1297 – ident: e_1_3_2_49_2 doi: 10.1016/0049-3848(90)90373-K – ident: e_1_3_2_13_2 doi: 10.1016/0026-0495(88)90157-6 – volume: 75 start-page: 921 year: 1996 ident: e_1_3_2_56_2 publication-title: Thromb Haemost doi: 10.1055/s-0038-1650395 – ident: e_1_3_2_21_2 doi: 10.1161/atv91.13.12.8241109 – ident: e_1_3_2_19_2 doi: 10.1016/0002-8703(90)90026-T – volume: 73 start-page: 568 year: 1995 ident: e_1_3_2_53_2 publication-title: Thromb Haemost doi: 10.1055/s-0038-1653822 – ident: e_1_3_2_50_2 doi: 10.1016/0895-4356(94)90298-4 – ident: e_1_3_2_51_2 doi: 10.2337/diab.43.1.104 – ident: e_1_3_2_14_2 doi: 10.2337/diab.36.8.897 – ident: e_1_3_2_44_2 doi: 10.2337/diab.42.2.250 – ident: e_1_3_2_45_2 doi: 10.2337/diab.43.9.1114 – ident: e_1_3_2_5_2 doi: 10.1161/circ.93.10.1809 – ident: e_1_3_2_29_2 doi: 10.1016/S0021-9150(96)06070-4 – volume: 334 start-page: 952 year: 1996 ident: e_1_3_2_3_2 publication-title: Med – ident: e_1_3_2_2_2 – ident: e_1_3_2_35_2 doi: 10.1093/oxfordjournals.aje.a113956 – volume: 117 start-page: 67 year: 1993 ident: e_1_3_2_48_2 publication-title: Arch Pathol Lab Med – ident: e_1_3_2_60_2 doi: 10.1007/BF02374497 – ident: e_1_3_2_6_2 doi: 10.2337/diacare.13.6.631 – ident: e_1_3_2_40_2 doi: 10.2337/diab.44.4.437 – ident: e_1_3_2_54_2 doi: 10.1055/s-0038-1646997 – ident: e_1_3_2_59_2 doi: 10.2337/diacare.19.2.157 – ident: e_1_3_2_4_2 doi: 10.1093/oxfordjournals.aje.a116768 – ident: e_1_3_2_22_2 doi: 10.1016/0026-0495(90)90164-8 – ident: e_1_3_2_39_2 doi: 10.1042/bj2600535 – ident: e_1_3_2_41_2 doi: 10.1210/edrv-6-1-45 – ident: e_1_3_2_17_2 doi: 10.3109/07853899608999095 – ident: e_1_3_2_23_2 doi: 10.1007/BF00402183 – ident: e_1_3_2_52_2 doi: 10.1055/s-0038-1653762 – ident: e_1_3_2_18_2 doi: 10.7326/0003-4819-118-12-199306150-00008 – ident: e_1_3_2_20_2 doi: 10.2337/diacare.15.10.1245 – ident: e_1_3_2_28_2 doi: 10.1016/S0140-6736(89)91306-8 – ident: e_1_3_2_1_2 doi: 10.1111/j.0954-6820.1985.tb08888.x – ident: e_1_3_2_27_2 doi: 10.1007/BF00403280 – ident: e_1_3_2_61_2 doi: 10.1056/NEJM198408233110804 – ident: e_1_3_2_31_2 doi: 10.1161/circ.91.3.764 – ident: e_1_3_2_43_2 doi: 10.1210/jcem-71-6-1508 – ident: e_1_3_2_9_2 doi: 10.1093/oxfordjournals.aje.a113639 – ident: e_1_3_2_15_2 doi: 10.2337/diab.37.12.1595 – ident: e_1_3_2_26_2 doi: 10.1007/BF00400356 – ident: e_1_3_2_37_2 – ident: e_1_3_2_8_2 doi: 10.1056/NEJM198903163201105 – ident: e_1_3_2_25_2 doi: 10.1016/0026-0495(93)90005-9 – ident: e_1_3_2_24_2 doi: 10.1016/0026-0495(86)90209-X – ident: e_1_3_2_47_2 doi: 10.1159/000205234 – ident: e_1_3_2_58_2 doi: 10.2337/diab.41.7.890 – ident: e_1_3_2_42_2 doi: 10.1016/0169-2607(86)90106-9 – ident: e_1_3_2_63_2 doi: 10.1161/atvb.18.1.84 – ident: e_1_3_2_11_2 doi: 10.2337/diacare.14.3.173 – ident: e_1_3_2_38_2 doi: 10.1210/jcem-25-10-1375 – ident: e_1_3_2_10_2 doi: 10.1016/0026-0495(88)90133-3 – volume: 118 start-page: 1106 year: 1994 ident: e_1_3_2_46_2 publication-title: Arch Pathol Lab Med |
SSID | ssj0004220 |
Score | 2.1065567 |
Snippet | Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood.... Abstract —Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood.... |
SourceID | proquest pubmed pascalfrancis crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 562 |
SubjectTerms | African Continental Ancestry Group Arteriosclerosis - ethnology Arteriosclerosis - metabolism Asian Continental Ancestry Group Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Diabetes Mellitus, Type 2 - metabolism European Continental Ancestry Group Female Fibrinogen - metabolism Fibrinolysis - physiology Glucose Tolerance Test Humans Hyperinsulinism - ethnology Hyperinsulinism - metabolism Hypoglycemic Agents - blood Insulin - blood Insulin Resistance - physiology Male Medical sciences Middle Aged Plasminogen Activator Inhibitor 1 - blood Proinsulin - blood Regression Analysis Risk Factors |
Title | Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance: The Insulin Resistance Atherosclerosis Study (IRAS) |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-199903000-00014 https://www.ncbi.nlm.nih.gov/pubmed/10073958 https://www.proquest.com/docview/69618419 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqISEkhLhTYOAHJiFNCXGcOPZjVRgDNgSoQ3uLcnFAakmmJgXBb-C38hs4vtRJp04avERJ5Nhpzxef4-Q730HoGSWEVVRkXikz5kWyIB4XpfRKQUXFk6qgujbg8Xt2eBK9PY1PR6M_A9bSqsv94tfWvJL_sSqcA7uqLNl_sKzrFE7APtgXtmBh2F7KxobJ9l1Vnqtd5SqTHGIY5prs27WKaFGsILReaj2HA0Xzrxvo1uQKTN54RL33yPaPFC98_4Mr6gWTRvcVpkVTRKWzoaka4bWlus-ahVw65Dg5W6UA3bRwu-CEjYqBqsfwLV8fqXEdCdYKQfVRqQ1pNdkyc0H_yzUxQ0y-NDAz6aLh-59UtrCDzc_5PNubTvc4r818egTrdOd5wDEXBlSrttUvLf3-rYdRSljTvuxEHSTCi5lR5vKlnbzDyFMCaBuzuxigmA6m6th6AWmP-HaHwohOkvAns88-ET713XVD6e5zLtURHfUSi5E0ICl0kBKR0jRWIcOVEJY1quLGu48DdfswNOoZ9rdZKSro4MW5O9iIoq6fgb2yRWUqsWxbKkGbH41iX7RznXwxCKFmN9ENu_bBEwPkW2gk69vo6rFld9xBv9d4xkM846bCFs8YYIMBz7jHM-4a3ONZN9B4xqo11njGPZ6xwjN2eMYGz2oEi2fs8HwXnRy8mk0PPVstxCuUH_LKsOJEcoinOZeCB1lUZUEZkaTIpYjKioekCBS3MqElpxGlFZNxkmQhoyWTYUzvoZ26qeUDhCuIckORM8nKOIL1eU6TXGQyhr0wDygdI3_976eFldJXFV0W6QX2HqPn7oIzoyJzcdPdDXP27ZW0Judj9HRt3hQ8gfq8l9WyWbUp08WbiBij-8bqg6H093i41tuAQWpyrVPNB2BKkhieNPD6RmyCRA8vf9uP0LX-MX2MdrrlSu5CuN7lTzTG_wIWmufa |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relative+Contribution+of+Insulin+and+Its+Precursors+to+Fibrinogen+and+PAI-1+in+a+Large+Population+With+Different+States+of+Glucose+Tolerance&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Festa%2C+Andreas&rft.au=D%E2%80%99Agostino%2C+Ralph&rft.au=Mykka%CC%88nen%2C+Leena&rft.au=Tracy%2C+Russell+P.&rft.date=1999-03-01&rft.issn=1079-5642&rft.eissn=1524-4636&rft.volume=19&rft.issue=3&rft.spage=562&rft.epage=568&rft_id=info:doi/10.1161%2F01.ATV.19.3.562&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_01_ATV_19_3_562 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |